Award
NIH Reporter #5K99CA304511-02
Enhancing Prostate Cancer Treatment Outcomes with Combined Radioimmunotherapy and Antibody Drug Conjugates
Recipient
Not specified
Award Amount
$185,760.00
Ceiling
$185,760.00
Awarded
June 11, 2026
Identifier
5K99CA304511-02
Award for developing a novel combination therapy for advanced prostate cancer using antibody-drug conjugates and alpha particle therapy to improve treatment efficacy and reduce toxicity.
Description
This project focuses on developing a novel tumor-targeted combination therapy for advanced prostate cancer, employing antibody-drug conjugates and alpha particle therapy to enhance efficacy and reduce toxicity. The project involves developing dual-labeled antibodies, constructing resistant tumor models, and expanding targeting strategies to multiple antigens.